Orexin-1 receptor antagonism fails to reduce anxiety-like behaviour in either plus-maze-naïve or plus-maze-experienced mice

Behavioural Brain Research

Volumn 243, Issue 1, 2013, Pages 213-219

  Rodgers, R J ^a   Wright, F L ^a   Snow, N F ^a   Taylor, L J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Anxiety; Chlordiazepoxide; Ethological analysis; Mice; Orexins; Plus maze; Prior test experience; SB 334867

Indexed keywords

1 (2 METHYL 6 BENZOXAZOLYL) 3 (1,5 NAPHTHYRIDIN 4 YL)UREA; CHLORDIAZEPOXIDE; OREXIN 1 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; AVOIDANCE BEHAVIOR; BEHAVIOR DISORDER; BEHAVIORAL SCIENCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; ETHOLOGY; EXPERIENCE; EXPLORATORY BEHAVIOR; MALE; MAZE TEST; MOUSE; NONHUMAN; PLUS MAZE; PRIORITY JOURNAL; RISK REDUCTION; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BENZOXAZOLES; CHLORDIAZEPOXIDE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MAZE LEARNING; MICE; NEUROPEPTIDES; NEUROPSYCHOLOGICAL TESTS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROPEPTIDE; UREA;

EID: 84873510184     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.12.064     Document Type: Article

References (84)

1. Aston-Jones G., Smith R.J., Sartor G.C., Moorman D.E., Massi L., Tahsili-Fahadan P., et al. Lateral hypothalamic orexin/hypocretin neurons: a role in reward-seeking and addiction. Brain Research 2010, 1314:74-90.
2. Avolio E., Alo R., Carelli A., Canonaco M. Amygdalar orexinergic-GABAergic interactions regulate anxiety behaviors of the Syrian golden hamster. Behavioural Brain Research 2011, 218:288-295.
3. Bäckberg M., Hervieu G., Wilson S., Meister B. Orexin receptor-1 (OX-R1) immunoreactivity in chemically identified neurons of the hypothalamus: focus on orexin targets involved in control of food and water intake. European Journal of Neuroscience 2002, 15:315-328.
4. Baldo R.A., Daniel R.A., Berridge C.W., Kelley A.E. Overlapping distributions of orexin/hypocretin- and dopamine-beta-hydroxylase immunoreactive fibers in rat brain regions mediating arousal, motivation, and stress. Journal of Comparative Neurology 2003, 464:220-237.
5. Bertoglio L.J., Carobrez A.P. Previous experience required to increase open arms avoidance in rats submitted to the elevated plus-maze model of anxiety. Behavioural Brain Research 2000, 108:197-203.
6. Bisetti A., Cvetkovic V., Serafin M., Bayer L., Machard D., Jones B.E., et al. Excitatory action of hypocretin/orexin on neurons in the central medial amygdala. Neuroscience 2006, 142:990-1004.
7. Boutrel B., Cannella N., de Lecea L. The role of hypocretin in driving arousal and goal-oriented behaviors. Brain Research 2010, 1314:103-111.
8. Brisbare-Roch C., Dingemanse J., Koberstein R., Hoever P., Aissaoui H., Flores S., et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nature Medicine 2007, 13:150-155.
9. Carobrez A.P., Bertoglio L.J. Ethological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20 years on. Neuroscience & Biobehavioral Reviews 2005, 29:1193-1205.
10. Cutler D.J., Morris R., Sheridhar V., Wattam T.A.K., Holmes S., Patel S., et al. Differential distribution of orexin-A and orexin-B immunoreactivity in the rat brain and spinal cord. Peptides 1999, 20:1455-1470.
11. Date Y., Ueta Y., Yamashita H., Yamaguichi H., Matsukara S., Kangawa K., et al. Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:748-753.
12. de Lecea L., Sutcliffe J.G. The hypocretins/orexins: novel hypothalamic neuropeptides involved in different physiological systems. Cellular and Molecular Life Sciences 1999, 56:473-480.
13. de Lecea L., Kilduff T.S., Peyron C., Gao X.-B., Foye P.E., Danielson P.E., et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:322-327.
14. Di Sebastiano A.R., Yong-Yow S., Wagner L., Lehman M.N., Coolen L.M. Orexin mediates initiation of sexual behavior in sexually naïve male rats, but is not critical for sexual performance. Hormones and Behavior 2010, 58:397-404.
15. Duxon M.S., Stretton J., Starr K., Jones D.N., Holland V., Riley G., et al. Evidence that orexin-A-evoked grooming in the rat is mediated by orexin-1 (OX1) receptors, with downstream 5-HT2C receptor involvement. Psychopharmacology 2001, 153:203-209.
16. Espana R.A., Valentino R.J., Berridge K.C. Fos immunoreactivity in hypocretin-synthesizing and hypocretin-1 receptor-expressing neurons: effects of diurnal and nocturnal spontaneous waking, stress and hypocretin-1 administration. Neuroscience 2003, 121:201-217.
17. Espejo E.F. Structure of mouse behavior on the elevated plus-maze test of anxiety. Behavioural Brain Research 1997, 86:105-112.
18. File S.E. One trial tolerance to the anxiolytic effects of chlordiazepoxide in the plus-maze. Psychopharmacology 1990, 100:281-282.
19. File S.E. Behavioural detection of anxiolytic action. Experimental approaches to anaxiety and depression 1992, 25-44. Wiley, Chichester. J.M. Elliott, D.J. Heal, C.A. Marsden (Eds.).
20. File S.E., Zangrossi H.J. One-trial tolerance to the anxiolytic actions of benzodiazepines in the elevated plus-maze, or the development of a phobic state?. Psychopharmacology 1993, 110:240-244.
21. File S.E., Zangrossi H., Sanders F.L., Mabbutt P.S. Raised corticosterone in the rat after exposure to the elevated plus-maze. Psychopharmacology 1994, 113:543-546.
22. Furlong T., Carrive P. Neurotoxic lesions centered on the perifornical hypothalamus abolish the cardiovascular and behavioral responses of conditioned fear but not of restraint. Brain Research 2007, 1128:107-119.
23. Furlong T.M., Vianna D.M.L., Liu L., Carrive P. Hypocretin/orexin contributes to the expression of some but not all forms of stress and arousal. European Journal of Neuroscience 2009, 30:1603-1614.
24. Greco M.A., Shiromani P.J. Hypocretin receptor protein and mRNA expression in the dorsolateral pons of rats. Molecular Brain Research 2001, 88:176-182.
25. Hagan J.J., Leslie R.A., Patel S., Evans M.L., Wattam T.A., Holmes S., et al. Orexin-A activates locus coeruleus cell firing and increases arousal in the rat. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:10911-10916.
26. Hervieu G.J., Cluderay J.E., Harrison D.C., Roberts J.C., Leslie R.A. Gene expression and protein distribution of the orexin-1 receptor in the rat brain and spinal cord. Neuroscience 2001, 103:777-797.
27. Holmes A., Rodgers R.J. Responses of Swiss-Webster mice to repeated plus-maze experience: further evidence of a qualitative shift in emotional state?. Pharmacology Biochemistry and Behavior 1998, 60:473-488.
28. Holmes A., Rodgers R.J. Influence of spatial and temporal manipulations on the anxiolytic efficacy of chlordiazepoxide in mice previously exposed to the elevated plus-maze. Neuroscience & Biobehavioral Reviews 1999, 23:971-980.
29. Ida T., Nakahara K., Katayama T., Muramaki N., Nakazato M. Effect of lateral cerebroventricular injection of appetite-stimulating neuropeptides, orexin and neuropeptide Y, on the various behavioral activities of rats. Brain Research 1999, 821:526-529.
30. Ida T., Nakahara K., Kuroiwa T., Fukui K., Nakazato M., Murakami T., et al. Both corticotropin releasing factor and neuropeptide Y are involved in the effect of orexin (hypocretin) on the food intake in rats. Neuroscience Letters 2000, 293:119-122.
31. Ishii Y., Blundell J.E., Halford J.C.G., Upton N., Porter R., Johns A., et al. Anorexia and weight loss in male rats 24h following single dose treatment with orexin-1 receptor antagonist SB-334867. Behavioural Brain Research 2005, 157:331-341.
32. Ishii Y., Blundell J.E., Halford J.C.G., Upton N., Porter R., Johns A., et al. Satiety enhancement by selective orexin-1 receptor antagonist SB-334867: influence of test context and profile comparison with CCK-8S. Behavioural Brain Research 2005, 160:11-24.
33. 2-mediated anxiety and hypertension but not bradycardia. Neuropsychopharmacology 2012, 37:1911-1922.
34. Johnson P.L., Truitt W., Fitz S.D., Minick P.E., Dietrich A., Sanghani S., et al. A key role for orexin in panic anxiety. Nature Medicine 2010, 16:111-115.
35. Kayaba Y., Nakamura A., Kasuya Y., Ohuchi T., Yanagisawa M., Komuro I., et al. Attenuated defense response and low basal blood pressure in orexin knockout mice. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 2003, 285:R581-R593.
36. Kukkonen J.P., Holmqvist T., Ammoun S., Akerman K.E.O. Functions of the orexigenic/hypocretinergic system. American Journal of Physiology: Cell Physiology 2002, 283:C1567-C1591.
37. Kuru M., Ueta Y., Serino R., Nakazato M., Yamamoto Y., Shibuya I., et al. Centrally administered orexin/hypocretin activates HPA axis in rats. NeuroReport 2000, 11:1977-1980.
38. Le Doux J.E. The emotional brain, fear, and the amygdala. Cellular and Molecular Neurobiology 2003, 23:727-738.
39. Li Y., Li S., Sui N., Kirouac G.J. Orexin-A acts on the paraventricular nucleus of the midline thalamus to inhibit locomotor activity in rats. Pharmacology Biochemistry and Behavior 2009, 93:506-514.
40. Li Y., Li S., Wei C., Wang H., Sui N., Kirouac G.J. Orexins in the paraventricular nucleus of the thalamus mediate anxiety-like responses in rats. Psychopharmacology 2010, 212:251-265.
41. Li Y., Li S., Wei C., Wang H., Sui N., Kirouac G.J. Changes in emotional behavior produced by orexin microinjections in the paraventricular nucleus of the thalamus. Pharmacology Biochemistry and Behavior 2010, 95:121-128.
42. Lister R.G. The use of the plus-maze to measure anxiety in the mouse. Psychopharmacology 1987, 92:180-185.
43. Marcus J.N., Aschkenasi C.J., Lee C.E., Chemelli R.M., Saper C., Yanagisawa M., et al. Differential expression of orexin receptors 1 and 2 in the rat brain. Journal of Comparative Neurology 2001, 435:6-25.
44. Mathiasen L.S., Mirza N.R., Rodgers R.J. Strain- and model-dependent effects of chlordiazepoxide, L-838,417 and zolpidem on anxiety-like behaviours in laboratory mice. Pharmacology Biochemistry and Behavior 2008, 90:19-36.
45. Mieda M., Yanagisawa M. Sleep, feeding and neuropeptides: roles of orexins and orexin receptors. Current Opinion in Neurobiology 2002, 12:339-345.
46. Nambu T., Sakurai T., Mizukami K., Hosoya Y., Yanagisawa M., Goto K. Distribution of orexin neurons in the adult rat brain. Brain Research 1999, 827:243-260.
47. Nishino S. The hypothalamic peptidergic system, hypocretin/orexin and vigilance control. Neuropeptides 2007, 41:117-133.
48. Peyron C., Tighe D.K., van den Pol A.N., de Lecea L., Heller H.C., Sutcliffe J.G., et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. Journal of Neuroscience 1998, 18:9996-10015.
49. Plaza-Zabala A., Martin-Garcia E., de Lecea L., Maldonado R., Berrendero F. Hypocretins regulate the anxiogenic-like effects of nicotine and induce reinstatement of nicotine-seeking behavior. Journal of Neuroscience 2010, 30:2300-2310.
50. Porter R.A., Chan W.N., Coulton S., Johns A., Hadley M.S., Widdowson K., et al. 1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor. Bioorganic & Medicinal Chemistry Letters 2001, 11:1907-1910.
51. Rodgers R.J. Animal tests for anxiety. Encyclopedia of behavioural neuroscience 2010, vol. 1:90-100. Academic Press, Oxford.
52. Rodgers R.J., Johnson N.J.T. Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacology Biochemistry and Behavior 1995, 52:297-303.
53. Rodgers R.J., Shepherd J.K. Influence of prior maze experience on behaviour and response to diazepam in tnhe elevated plus-maze and light/dark tests of anxiety in mice. Psychopharmacology 1993, 113:237-242.
54. Rodgers R.J., Gentsch C., Hoyer D., Bryant E., Green A.J., Kolokotroni K.Z., et al. (NK1) receptor antagonist, NKP608, is devoid of anxiolytic-like activity in the mouse elevated plus-maze. Behavioural Brain Research 2004, 154:183-192.
55. Rodgers R.J., Halford J.C.G., Nunes de Souza R.L., Canto de Souza A.L., Piper D.C., Arch J.R.S., et al. SB-334867, a selective orexin-1 receptor antagonist, enhances behavioural satiety and blocks the hyperphagic effect of orexin-A in rats. European Journal of Neuroscience 2001, 13:1444-1452.
56. Rodgers R.J., Haller J., Halasz J., Mikics E. 'One-trial sensitisation' to the anxiolytic-like effects of cannabinoid receptor antagonist SR 141716A in the mouse elevated plus-maze. European Journal of Neuroscience 2003, 17:1279-1286.
57. Rodgers R.J., Haller J., Holmes A., Halasz J., Walton T.J., Brain P.F. Corticosterone response to the plus-maze: high correlation with risk assessment in rats and mice. Physiology and Behavior 1999, 68:47-53.
58. Rodgers R.J., Howard K., Stewart S., Waring P., Wright F.L. Anxioselective profile of glycineB receptor partial agonist, d-cycloserine, in plus-maze naïve but not plus-maze-experienced mice. European Journal of Pharmacology 2010, 646:31-37.
59. Rodgers R.J., Ishii Y., Halford J.C.G., Blundell J.E. Orexins and appetite regulation. Neuropeptides 2002, 36:303-325.
60. Roy V., Chapillon P., Jeljeli M., Caston J., Belzung C. Free versus forced exposure to an elevated plus-maze: evidence for new behavioural interpretations during test and retest. Psychopharmacology 2009, 203:131-141.
61. Sakamoto F., Yamada S., Ueta Y. Centrally administered orexin-A activates corticotropin-releasing factor-containing neurons in the hypothalamic paraventricular nucleus and central amygdaloid nucleus of rats: possible involvement of central orexins on stress-activated central CRF neurons. Regulatory Peptides 2004, 118:183-191.
62. Sakurai T. Roles of orexins in regulation of feeding and wakefulness. NeuroReport 2002, 13:987-995.
63. Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nature Reviews Neuroscience 2007, 8:171-181.
64. Sakurai T., Mieda M. Connectomics of orexin-producing neurons: interface of systems of emotion, energy homeostasis and arousal. TIPS 2011, 32:451-462.
65. Sakurai T., Amemiya A., Ishii M., Matsuzaki I., Chemelli R.M., Tanaka H., et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998, 92:573-585.
66. Schmidt O., Usunoff K.G., Lazarov N.E., Itzev D.E., Eipert P., Rolfs A., et al. Orexigenic innervation of the extended amygdala and basal ganglia in the rat. Brain Structure & Function 2011, 217:233-256.
67. Scott M.M., Marcus J.N., Pettersein A., Birnbaum S.G., Mochizuki T., Scammel T.E., et al. Hcrtr1 and 2 signaling differentially regulates depression-like behaviors. Behavioural Brain Research 2011, 222:289-294.
68. Shirasaka T., Nakazato M., Matsukura S., Takasaki M., Kannan H. Sympathetic and cardiovascular actions of orexins in conscious rats. American Journal of Physiology 1999, 277:R1780-R1785.
69. Singareddy R., Uhde T., Commissaris B. Differential effects of hypocretins on noise-alone versus potentiated startle responses. Physiology and Behavior 2006, 89:650-655.
70. Smart D., Haynes A.C., Williams G., Arch J.R.S. Orexins and the treatment of obesity. European Journal of Pharmacology 2002, 440:199-212.
71. Smart D., Jerman J.C., Brough S.J., Rushton S.L., Murdock P.R., Jewitt F., et al. Characterisation of recombinant human orexin receptor pharmacology in a Chinese hamsetr ovary cell line using FLIPR. British Journal of Pharmacology 1999, 128:1-3.
72. Smart D., Sabido-David C., Brough S.J., Jewitt F., Johns A., Porter R.A., et al. SB-334867-A: the first selective orexin-1 receptor antagonist. British Journal of Pharmacology 2001, 132:1179-1182.
73. Steiner M.A., Lecourt H., Jenck F. The brain orexin system and almorexant in fear conditioned startle reactions in the rat. Psychopharmacology 2012, 223:465-475.
74. Suzuki M., Beuckmann C.T., Shikata K., Ogura H., Saway T. Orexin-A (hypocretin-1) is possibly involved in generation of anxiety-like behavior. Brain Research 2005, 1044:116-121.
75. Taheri S., Mahmoodi M., Opacka-Juffry J., Ghatei M.A., Bloom S.R. Distribution and quantification of orexin A in rat tissues. FEBS Letters 1999, 457:157-161.
76. Treit D., Menard J., Royan C. Anxiogenic stimuli in the elevated plus-maze. Pharmacology Biochemistry and Behavior 1993, 33:463-469.
77. Tsujino N., Sakurai T. Orexin/hypocretin: a neuropeptide at the interface of sleep, energy homesostasis, and reward system. Pharmacological Reviews 2009, 61:162-176.
78. Weiss SM. Pharmacological and behavioural examination of the defensive reactions of laboratory mice to the calls of the Tawny Owl. PhD Thesis. University of Leeds. 1995.
79. Willie J.T., Chemelli R.M., Sinton C.M., Yanagisawa M. To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annual Review of Neuroscience 2001, 24:429-458.
80. Winksy-Sommerer R., Yamanaka A., Diano S., Borok E., Roberts A.J., Sakurai T., et al. Interaction between the coticotropin-releasing factor system and hypocretins (orexins): a novel circuit mediating stress response. Journal of Neuroscience 2004, 24:11439-11448.
81. Yamanaka A., Beuckmann C.T., Willie J.T., Hara J., Tsujino N., Mieda M., et al. Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron 2003, 38:701-713.
82. Yoshida K., McCormack S., Espana R.A., Crocker A., Scammell T.E. Afferents to the orexin neurons of the rat brain. Journal of Comparative Neurology 2006, 494:845-861.
83. Zhang W., Shimoyama M., Fukuda Y., Kuwaki T. Multiple components of the defense response depend on orexin: evidence from orexin knockout and orexin neuron-ablated mice. Autonomic Neuroscience 2006, 126-127:139-145.
84. Zhu L., Onaka T., Sakurai T., Yada T. Activation of orexin neurones after noxious but not conditioned fear stimuli in rats. NeuroReport 2002, 13:1351-1353.